SRPT Annual EBITDA
-$453.69 M
+$141.16 M+23.73%
31 December 2023
Summary:
As of January 22, 2025, SRPT annual earnings before interest, taxes, depreciation & amortization is -$453.69 million, with the most recent change of +$141.16 million (+23.73%) on December 31, 2023. During the last 3 years, it has risen by +$12.52 million (+2.68%). SRPT annual EBITDA is now -26587.71% below its all-time high of -$1.70 million, reached on December 31, 1996.SRPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Quarterly EBITDA
$48.73 M
+$21.60 M+79.63%
30 September 2024
Summary:
As of January 22, 2025, SRPT quarterly earnings before interest, taxes, depreciation & amortization is $48.73 million, with the most recent change of +$21.60 million (+79.63%) on September 30, 2024. Over the past year, it has dropped by -$8.25 million (-14.47%). SRPT quarterly EBITDA is now -44.61% below its all-time high of $87.98 million, reached on March 31, 2017.SRPT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT TTM EBITDA
$187.19 M
+$65.75 M+54.14%
30 September 2024
Summary:
As of January 22, 2025, SRPT TTM earnings before interest, taxes, depreciation & amortization is $187.19 million, with the most recent change of +$65.75 million (+54.14%) on September 30, 2024. Over the past year, it has increased by +$640.88 million (+141.26%). SRPT TTM EBITDA is now at all-time high.SRPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.7% | -14.5% | +141.3% |
| 3 y3 years | +2.7% | +121.1% | +130.9% |
| 5 y5 years | -43.3% | +121.1% | +130.9% |
SRPT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -42.9% | +23.7% | -14.5% | +109.8% | at high | +118.5% |
| 5 y | 5-year | -42.9% | +31.1% | -14.5% | +109.8% | at high | +118.5% |
| alltime | all time | <-9999.0% | +31.1% | -44.6% | +109.8% | at high | +118.5% |
Sarepta Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $48.73 M(+79.6%) | $187.19 M(+54.1%) |
| June 2024 | - | $27.13 M(-50.1%) | $121.45 M(+26.8%) |
| Mar 2024 | - | $54.36 M(-4.6%) | $95.75 M(-121.1%) |
| Dec 2023 | -$453.69 M(-23.7%) | $56.98 M(-434.8%) | -$453.69 M(-23.7%) |
| Sept 2023 | - | -$17.02 M(-1289.2%) | -$594.73 M(-26.5%) |
| June 2023 | - | $1.43 M(-100.3%) | -$808.70 M(-20.1%) |
| Mar 2023 | - | -$495.08 M(+488.9%) | -$1.01 B(+70.2%) |
| Dec 2022 | -$594.85 M(+87.4%) | -$84.06 M(-63.6%) | -$594.85 M(-1.9%) |
| Sept 2022 | - | -$230.98 M(+14.2%) | -$606.48 M(+52.8%) |
| June 2022 | - | -$202.18 M(+160.4%) | -$396.92 M(+57.4%) |
| Mar 2022 | - | -$77.63 M(-18.9%) | -$252.22 M(-20.5%) |
| Dec 2021 | -$317.41 M(-31.9%) | -$95.70 M(+346.8%) | -$317.41 M(-17.4%) |
| Sept 2021 | - | -$21.42 M(-62.7%) | -$384.18 M(-28.7%) |
| June 2021 | - | -$57.48 M(-59.8%) | -$538.65 M(-12.0%) |
| Mar 2021 | - | -$142.81 M(-12.1%) | -$611.79 M(+31.2%) |
| Dec 2020 | -$466.21 M(-29.2%) | -$162.47 M(-7.6%) | -$466.21 M(-11.0%) |
| Sept 2020 | - | -$175.90 M(+34.7%) | -$523.70 M(+13.9%) |
| June 2020 | - | -$130.61 M(-4820.3%) | -$459.64 M(-22.3%) |
| Mar 2020 | - | $2.77 M(-101.3%) | -$591.60 M(-10.2%) |
| Dec 2019 | -$658.71 M(+108.0%) | -$219.96 M(+96.7%) | -$658.71 M(+15.6%) |
| Sept 2019 | - | -$111.84 M(-57.4%) | -$569.65 M(+9.4%) |
| June 2019 | - | -$262.57 M(+308.1%) | -$520.61 M(+46.4%) |
| Mar 2019 | - | -$64.34 M(-50.8%) | -$355.66 M(+12.3%) |
| Dec 2018 | -$316.66 M(+811.6%) | -$130.90 M(+108.5%) | -$316.66 M(+54.5%) |
| Sept 2018 | - | -$62.79 M(-35.7%) | -$205.00 M(+11.1%) |
| June 2018 | - | -$97.63 M(+285.3%) | -$184.57 M(+24.7%) |
| Mar 2018 | - | -$25.34 M(+31.7%) | -$148.06 M(+326.2%) |
| Dec 2017 | -$34.73 M(-86.6%) | -$19.24 M(-54.6%) | -$34.74 M(-65.8%) |
| Sept 2017 | - | -$42.36 M(-30.7%) | -$101.51 M(-11.4%) |
| June 2017 | - | -$61.12 M(-169.5%) | -$114.61 M(+0.5%) |
| Mar 2017 | - | $87.98 M(-202.3%) | -$114.00 M(-56.2%) |
| Dec 2016 | -$259.76 M(+21.7%) | -$86.01 M(+55.1%) | -$260.29 M(+10.4%) |
| Sept 2016 | - | -$55.46 M(-8.3%) | -$235.84 M(+2.2%) |
| June 2016 | - | -$60.51 M(+3.8%) | -$230.83 M(+9.3%) |
| Mar 2016 | - | -$58.30 M(-5.3%) | -$211.14 M(-1.1%) |
| Dec 2015 | -$213.42 M(+64.0%) | -$61.57 M(+22.0%) | -$213.42 M(+9.2%) |
| Sept 2015 | - | -$50.45 M(+23.6%) | -$195.41 M(+10.0%) |
| June 2015 | - | -$40.82 M(-32.6%) | -$177.59 M(+6.9%) |
| Mar 2015 | - | -$60.58 M(+39.1%) | -$166.08 M(+27.7%) |
| Dec 2014 | -$130.10 M(+46.2%) | -$43.56 M(+33.5%) | -$130.10 M(+9.2%) |
| Sept 2014 | - | -$32.63 M(+11.3%) | -$119.11 M(+7.2%) |
| June 2014 | - | -$29.31 M(+19.2%) | -$111.13 M(+12.7%) |
| Mar 2014 | - | -$24.60 M(-24.5%) | -$98.64 M(+10.8%) |
| Dec 2013 | -$89.01 M(+215.9%) | -$32.57 M(+32.2%) | -$89.01 M(+34.1%) |
| Sept 2013 | - | -$24.65 M(+46.5%) | -$66.37 M(+37.5%) |
| June 2013 | - | -$16.83 M(+12.4%) | -$48.25 M(+31.8%) |
| Mar 2013 | - | -$14.96 M(+50.7%) | -$36.62 M(+30.0%) |
| Dec 2012 | -$28.18 M(-18.6%) | -$9.93 M(+52.1%) | -$28.18 M(+5.5%) |
| Sept 2012 | - | -$6.53 M(+25.7%) | -$26.71 M(-14.3%) |
| June 2012 | - | -$5.20 M(-20.3%) | -$31.18 M(-13.0%) |
| Mar 2012 | - | -$6.52 M(-22.9%) | -$35.86 M(+3.5%) |
| Dec 2011 | -$34.63 M(+77.8%) | -$8.46 M(-23.0%) | -$34.63 M(+25.9%) |
| Sept 2011 | - | -$11.00 M(+11.4%) | -$27.49 M(+37.9%) |
| June 2011 | - | -$9.87 M(+86.6%) | -$19.94 M(+14.7%) |
| Mar 2011 | - | -$5.29 M(+297.9%) | -$17.38 M(-10.8%) |
| Dec 2010 | -$19.47 M | -$1.33 M(-61.4%) | -$19.48 M(-10.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$3.44 M(-53.0%) | -$21.81 M(+4.2%) |
| June 2010 | - | -$7.32 M(-1.0%) | -$20.93 M(+14.2%) |
| Mar 2010 | - | -$7.39 M(+101.9%) | -$18.32 M(+29.7%) |
| Dec 2009 | -$14.13 M(-12.1%) | -$3.66 M(+42.8%) | -$14.13 M(+9.2%) |
| Sept 2009 | - | -$2.56 M(-45.6%) | -$12.94 M(-19.0%) |
| June 2009 | - | -$4.71 M(+47.2%) | -$15.97 M(+1.1%) |
| Mar 2009 | - | -$3.20 M(+29.5%) | -$15.79 M(-1.8%) |
| Dec 2008 | -$16.07 M(-48.3%) | -$2.47 M(-55.8%) | -$16.07 M(-14.3%) |
| Sept 2008 | - | -$5.59 M(+23.4%) | -$18.77 M(-11.3%) |
| June 2008 | - | -$4.53 M(+30.1%) | -$21.15 M(-15.3%) |
| Mar 2008 | - | -$3.48 M(-32.5%) | -$24.97 M(-19.7%) |
| Dec 2007 | -$31.09 M(+0.7%) | -$5.16 M(-35.3%) | -$31.09 M(-9.0%) |
| Sept 2007 | - | -$7.97 M(-4.5%) | -$34.17 M(+3.7%) |
| June 2007 | - | -$8.35 M(-13.1%) | -$32.95 M(+4.6%) |
| Mar 2007 | - | -$9.61 M(+16.5%) | -$31.50 M(+2.0%) |
| Dec 2006 | -$30.89 M(+99.1%) | -$8.24 M(+22.1%) | -$30.89 M(+14.3%) |
| Sept 2006 | - | -$6.75 M(-2.3%) | -$27.03 M(+24.5%) |
| June 2006 | - | -$6.91 M(-23.2%) | -$21.70 M(+11.6%) |
| Mar 2006 | - | -$8.99 M(+105.6%) | -$19.45 M(+25.3%) |
| Dec 2005 | -$15.52 M(-33.0%) | -$4.38 M(+206.9%) | -$15.52 M(-0.3%) |
| Sept 2005 | - | -$1.43 M(-69.4%) | -$15.56 M(-19.2%) |
| June 2005 | - | -$4.66 M(-8.0%) | -$19.26 M(-11.8%) |
| Mar 2005 | - | -$5.06 M(+14.6%) | -$21.83 M(-9.4%) |
| Dec 2004 | -$23.16 M(+33.2%) | -$4.42 M(-13.8%) | -$24.10 M(-8.7%) |
| Sept 2004 | - | -$5.12 M(-29.2%) | -$26.38 M(+3.1%) |
| June 2004 | - | -$7.23 M(-1.3%) | -$25.59 M(+18.7%) |
| Mar 2004 | - | -$7.32 M(+9.3%) | -$21.57 M(+24.0%) |
| Dec 2003 | -$17.39 M(-27.6%) | -$6.70 M(+54.8%) | -$17.39 M(+20.3%) |
| Sept 2003 | - | -$4.33 M(+34.9%) | -$14.46 M(-4.6%) |
| June 2003 | - | -$3.21 M(+1.9%) | -$15.15 M(-22.4%) |
| Mar 2003 | - | -$3.15 M(-16.6%) | -$19.53 M(-18.7%) |
| Dec 2002 | -$24.01 M(+61.7%) | -$3.77 M(-24.9%) | -$24.01 M(-2.9%) |
| Sept 2002 | - | -$5.02 M(-33.7%) | -$24.73 M(+7.8%) |
| June 2002 | - | -$7.58 M(-0.6%) | -$22.93 M(+20.5%) |
| Mar 2002 | - | -$7.63 M(+69.7%) | -$19.03 M(+28.2%) |
| Dec 2001 | -$14.85 M(+51.1%) | -$4.50 M(+39.3%) | -$14.85 M(+9.0%) |
| Sept 2001 | - | -$3.23 M(-12.2%) | -$13.62 M(+5.6%) |
| June 2001 | - | -$3.68 M(+6.6%) | -$12.90 M(+6.6%) |
| Mar 2001 | - | -$3.45 M(+5.4%) | -$12.10 M(+23.2%) |
| Dec 2000 | -$9.82 M(+22.8%) | -$3.27 M(+30.6%) | -$9.82 M(+12.3%) |
| Sept 2000 | - | -$2.50 M(-13.0%) | -$8.75 M(+4.8%) |
| June 2000 | - | -$2.88 M(+146.6%) | -$8.35 M(+13.3%) |
| Mar 2000 | - | -$1.17 M(-46.9%) | -$7.37 M(-4.3%) |
| Dec 1999 | -$8.00 M(+5.3%) | -$2.20 M(+4.8%) | -$7.70 M(-4.9%) |
| Sept 1999 | - | -$2.10 M(+10.5%) | -$8.10 M(+5.2%) |
| June 1999 | - | -$1.90 M(+26.7%) | -$7.70 M(+4.1%) |
| Mar 1999 | - | -$1.50 M(-42.3%) | -$7.40 M(+1.4%) |
| Dec 1998 | -$7.60 M(+123.5%) | -$2.60 M(+52.9%) | -$7.30 M(+32.7%) |
| Sept 1998 | - | -$1.70 M(+6.3%) | -$5.50 M(+17.0%) |
| June 1998 | - | -$1.60 M(+14.3%) | -$4.70 M(+14.6%) |
| Mar 1998 | - | -$1.40 M(+75.0%) | -$4.10 M(+28.1%) |
| Dec 1997 | -$3.40 M(+100.0%) | -$800.00 K(-11.1%) | -$3.20 M(+33.3%) |
| Sept 1997 | - | -$900.00 K(-10.0%) | -$2.40 M(+60.0%) |
| June 1997 | - | -$1.00 M(+100.0%) | -$1.50 M(+200.0%) |
| Mar 1997 | - | -$500.00 K | -$500.00 K |
| Dec 1996 | -$1.70 M | - | - |
FAQ
- What is Sarepta Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual EBITDA year-on-year change?
- What is Sarepta Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly EBITDA year-on-year change?
- What is Sarepta Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM EBITDA year-on-year change?
What is Sarepta Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SRPT is -$453.69 M
What is the all time high annual EBITDA for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.70 M
What is Sarepta Therapeutics annual EBITDA year-on-year change?
Over the past year, SRPT annual earnings before interest, taxes, depreciation & amortization has changed by +$141.16 M (+23.73%)
What is Sarepta Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SRPT is $48.73 M
What is the all time high quarterly EBITDA for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $87.98 M
What is Sarepta Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SRPT quarterly earnings before interest, taxes, depreciation & amortization has changed by -$8.25 M (-14.47%)
What is Sarepta Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SRPT is $187.19 M
What is the all time high TTM EBITDA for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $187.19 M
What is Sarepta Therapeutics TTM EBITDA year-on-year change?
Over the past year, SRPT TTM earnings before interest, taxes, depreciation & amortization has changed by +$640.88 M (+141.26%)